Newsletter 17 - June 2016


It is with great pleasure that we announce the recruitment of the first patients in COMBACTE-CARE’s REJUVENATE study. José Miguel Cisneros Herreros from the University Hospital Virgen del Rocio, Jesús Rodríguez-Baño and Luis Tallón's team from Hospital Universitario Virgen Macarena, enrolled the first patients on the 19th and 26th of May respectively. COMBACTE-CARE, a project with 18 academic and 3 pharmaceutical partners, led by AstraZeneca as the coordinator and The University of Utrecht as the managing entity, aims to better understand the clinical management and outcomes of hospitalized patients with (CRE) infections. Read more.. 


The first case in COMBACTE-MAGNET's study RESCUING was enrolled on December 23rd, 2015. Currently, 18 sites are actively enrolling cases and over 500 cases have been entered into the eCRF. Deadeadline for data completion was May 31st, 2016. The data will be analyzed starting in September and the study report should be available by December 2016. Thus far, the study appears to be on track. Read more..

EURECA has Started

Good news from EURECA (European prospective cohort study on Enterobacteriaeae showing REsistance to CArbapenems): after the initiation of the first two sites, the first patient was recruited in Hospital Reina Sofía (Córdoba, Spain) April 27th. Five more sites will be initiated in Spain in the coming weeks, and progress is being made with Institutional Review Board approvals.  Read more..

Introducing ANTICIPATE

COMBACTE-NET's newest study is ANTICIPATE: AssessmeNT of the Incidence of Clostridium difficile Infections in hospitalized Patients on Antibiotic TrEatment. It is an observational, prospective, cohort study of patients receiving antibiotic treatment during hospitalization. Read more..


Looking Back at ECCMID 2016

This year the hosting country of the 26th European Congress of Clinical Microbiology and Infectious Diseases was Amsterdam, The Netherlands at the RAI. COMBACTE was represented as 1 of the 160 booths in the exposition area with booth number 37A, to answer your questions and for a meet an great and held a COMBACTE Investigators lunch meeting on the Sunday. Read more..


More news

  • FDA Fast Track Status for CARBAVANCE by The Medicines Company Read more..
  • Building Sustainability for AMR and EID Research in Europe Read more..
  • COMBACTE 2016: On the Way to the Realization of the ND4BB Vision Read more..
  • DRIVE-AB Conference on Sustainable Development and use of Antibiotics Read more..


Please contact the PMO team with your ideas for the next newsletter.
Click here to send us your thoughts! Looking forward to hearing from you!

Unsubscribe from this newsletter.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.